Kidney Scan After a Child's Infection: Scar or Just Healing?
"Understanding DMSA Scans and Follow-Up Care After Pediatric Pyelonephritis"
As a parent, few things are more unsettling than a health scare involving your child. When a child is diagnosed with pyelonephritis, a type of kidney infection, the road to recovery can feel fraught with uncertainty. A common follow-up involves a DMSA (Dimercaptosuccinic acid) renal scan, an imaging test used to assess kidney health. However, what happens when that scan, performed months after the initial infection, reveals a lesion or abnormality?
The standard interpretation is that such lesions indicate permanent scarring, raising concerns about potential long-term complications like hypertension or kidney dysfunction. This is understandably alarming for parents. However, recent research suggests a more nuanced picture. A study published in the journal Revista Médica de Chile sheds light on the evolution of these lesions, questioning the assumption that they always represent irreversible damage.
This article will delve into the findings of this research, offering a clearer understanding of DMSA scans, the significance of lesions detected after pyelonephritis, and what this means for your child's follow-up care. We'll explore why a 'wait-and-see' approach might be more appropriate than immediately assuming the worst, providing you with the information needed to navigate this challenging situation with confidence.
DMSA Imaging During and After Infection
A study examined 43 children with acute pyelonephritis, whose mean age was 5.8 ± 3.6 years, using 99mTc-DMSA scans during the illness and again 8 ± 2 months later to evaluate a quantitative method for identifying kidneys at risk of scarring. Separately, reports noted that DMSA scans could show cortical defects in affected kidneys even when ultrasonography and intravenous urography were normal. These findings illustrate why a normal ultrasound alone may not rule out abnormalities visible on DMSA imaging.
DMSA’s Role in Understanding Kidney Infection
Clinical and experimental investigations using DMSA renal scintigraphy provided new insights into the causes, disease processes, and clinical outcomes of acute pyelonephritis in children. By 2019, a review described 99mTc-DMSA scanning as a way to help diagnose acute pyelonephritis during febrile urinary tract infections and to detect renal scarring on later scans. Together, these sources trace DMSA’s role from research into childhood kidney infection to its use for evaluating both acute disease and later cortical damage.
DMSA Scans: What Do They Really Tell Us?
A DMSA scan is a type of nuclear medicine imaging used to evaluate the structure and function of the kidneys. It's particularly useful in children who have experienced pyelonephritis, as it can detect subtle damage to the kidney tissue (parenchyma). The scan involves injecting a small amount of a radioactive tracer, DMSA, which is then absorbed by the kidney cells. A special camera detects the tracer, creating images of the kidneys. Areas with reduced tracer uptake may indicate damage or scarring.
- The Study's Key Findings: The researchers followed 85 children who had experienced acute pyelonephritis, performing DMSA scans during the acute phase (within 7 days of fever onset) and then again 5-7 months later. If lesions persisted, a third scan was performed at 10-13 months.
- Surprising Results: The study found that while 31% of the children had abnormal DMSA scans on the early follow-up (5-7 months), a significant portion of these lesions resolved on the later scan (10-13 months). Specifically, 21% of the kidney units that showed lesions at the early follow-up normalized by the late follow-up.
- Implications for Parents: This suggests that a lesion seen on a DMSA scan 6 months after pyelonephritis doesn't automatically equate to a permanent scar. In some cases, the kidney is still healing and the lesion may resolve over time.
What DMSA Screening Can and Cannot Show
A review of DMSA or ultrasound screening for vesicoureteral reflux (VUR) in children with urinary tract infections reported that a negative DMSA test corresponds to less than a 1% probability of high-grade VUR. However, the review also cautioned that screening DMSA would falsely label many children as being at risk for high-grade VUR. This underscores that a reassuring test result and the consequences of screening positive must both be considered.
Limits in Diagnosis and Interpretation
A Chilean pediatric nephrology recommendation notes that urinary tract infection can be difficult to diagnose and manage because symptoms may be nonspecific, test results can be difficult to interpret—especially in younger children—and the outlook for kidney damage is uncertain. Although Tc-99m DMSA is described as a method of choice for detecting acute pyelonephritis and cortical scarring, different acquisition methods have been used, including planar parallel-hole and pinhole imaging. A separate study specifically set out to examine the relative limitations of DMSA compared with computed tomography for diagnosing acute pyelonephritis in children.
Comparing DMSA Findings with Other Measures
In a study of 66 children aged 2 months to 6 years who were admitted with signs of a first febrile urinary tract infection, Doppler ultrasonography was compared with DMSA scintigraphy as a tool for predicting permanent kidney damage. Another report found that age, elevated C-reactive protein (PCR), and changes in renal volume were statistically associated with a greater likelihood of pathological DMSA findings. In a study of early imaging, DMSA scintigraphy performed a median of 10 days after treatment began was abnormal in 73 children (42%), equivocal in 29 (16%), and normal in 73 (42%).
What This Means for Your Child's Care: A More Balanced Approach
The Revista Médica de Chile study highlights the importance of a nuanced approach to interpreting DMSA scans in children after pyelonephritis. While a lesion detected at the 6-month mark should not be dismissed, it also shouldn't be automatically considered a permanent scar. Instead, a period of observation and a later follow-up scan may be warranted.
Interpretation Can Vary Between Readers
DMSA renal scintigraphy is described as the current standard for identifying renal scars in clinical practice. However, ongoing concerns include differences in scan methodology and variability both between readers and within an individual reader’s interpretations. These issues matter when scan findings are used to distinguish a lasting scar from other cortical changes.
Research Directions for DMSA Imaging
A review of clinical and experimental investigations described DMSA scintigraphy as a source of insights into the causes, processes, and clinical outcomes of acute pyelonephritis in children, and discussed future research applications. Another review linked the acute inflammatory response in both reflux and nonreflux pyelonephritis to the development of irreversible renal scarring, while also considering future research applications. These sources point to continued research into how infection and inflammation relate to lasting kidney damage.
This 'wait-and-see' approach can alleviate parental anxiety and potentially avoid unnecessary interventions. It's crucial to maintain regular check-ups with your child's pediatrician or nephrologist. They can monitor your child's blood pressure, urine, and kidney function, and determine the appropriate timing for a repeat DMSA scan. Your doctor will consider other factors, such as the severity of the initial infection, the presence of vesicoureteral reflux (VUR), and any recurrent urinary tract infections, to guide their decision-making.
Ultimately, the goal is to identify children who are truly at risk for long-term kidney complications and provide them with the necessary care. By understanding the evolving nature of kidney lesions after pyelonephritis, and by working closely with your child's healthcare team, you can ensure that your child receives the best possible care and support.